We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
NGENLA (Pfizer Australia Pty Ltd)
Product name
NGENLA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
182 (255 working days)
Active ingredients
somatrogon
Registration type
NCE/NBE
Indication
NGENLA (solution for injection) is indicated for the long-term treatment of paediatric patients with growth disturbance due to insufficient secretion of growth hormone.